Your browser version may not work well with NCBI's Web applications. More information here...
1: J Acquir Immune Defic Syndr. 2007 May 1;45(1):1-3. Links

Prospective screening for human leukocyte antigen-B*5701 avoids abacavir hypersensitivity reaction in the ethnically mixed French HIV population.

Zucman D, Truchis P, Majerholc C, Stegman S, Caillat-Zucman S.

Réseau Ville-Hopital Val de Seine, Hopital Foch, Suresnes, France.

The association of human leukocyte antigen-B*5701 with abacavir hypersensitivity varies depending on ethnic origin. We confirmed the high specificity of B*5701 in the ethnically mixed French population and used a rapid and inexpensive polymerase chain reaction strategy to evaluate the predictiveness of B*5701 screening. The incidence of hypersensitivity decreased from 12% before screening to 0% after screening, and the rate of unwarranted interruptions of abacavir therapy decreased from 10.2% to 0.73%. We therefore recommend the implementation of this cost-effective screen before treatment with abacavir.

PMID: 17356469 [PubMed - indexed for MEDLINE]

Patient Drug Information